The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 27, 2018

Filed:

Jan. 17, 2018
Applicant:

Pulse Biosciences, Inc., Hayward, CA (US);

Inventors:

Richard Lee Nuccitelli, Millbrae, CA (US);

Pamela S. Nuccitelli, Millbrae, CA (US);

Joanne Lum, San Francisco, CA (US);

Kaying Lui, Millbrae, CA (US);

Brian G. Athos, San Francisco, CA (US);

Mark P. Kreis, Sna Francisco, CA (US);

Zachary R. Mallon, San Francisco, CA (US);

Jon Berridge, Oakland, CA (US);

Assignee:

Pulse Biosciences, Inc., Hayward, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 1/00 (2006.01); A61N 1/30 (2006.01); A61M 3/00 (2006.01); A61K 35/13 (2015.01); A61N 1/36 (2006.01); A61B 18/14 (2006.01); C12N 13/00 (2006.01); A61N 1/05 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01); C12N 15/87 (2006.01); A61B 18/00 (2006.01); A61N 1/40 (2006.01); C12M 1/42 (2006.01); A61N 1/04 (2006.01); A61N 1/32 (2006.01); A61N 1/372 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/13 (2013.01); A61B 18/1477 (2013.01); A61K 31/704 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61N 1/05 (2013.01); A61N 1/32 (2013.01); A61N 1/36 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C12N 5/0693 (2013.01); C12N 13/00 (2013.01); G01N 33/574 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00613 (2013.01); A61K 2039/505 (2013.01); A61N 1/0412 (2013.01); A61N 1/0424 (2013.01); A61N 1/327 (2013.01); A61N 1/37229 (2013.01); A61N 1/40 (2013.01); C07K 2317/76 (2013.01); C12M 35/02 (2013.01); C12N 15/87 (2013.01); C12N 2501/599 (2013.01); C12N 2501/999 (2013.01);
Abstract

A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.


Find Patent Forward Citations

Loading…